

Radiological findings :.....

Details of previous biopsy or cytology report :.....

Immunohistochemistry study report:.....

ER, PR, Her2 neu status:.....

Drug Details: (PDL-1 IHC indicated in patients with specific tumor type in order to predict their responses to treatment with PDL-1 inhibitors. The specific PDL-1 clone scoring method and eligibility requirements are dependant on the tumor type, stage of malignancy, previous treatment outcomes and specific PDL-1 inhibitors being considered)

| Tick | Clone | Drug |
|--------------------------|-------|---|
| <input type="checkbox"/> | Sp263 | Nivolumab (opdivo) |
| <input type="checkbox"/> | Sp263 | Durvalumab (imfinzi) |
| <input type="checkbox"/> | Sp142 | Atezolilumab (Tecentriq) |
| <input type="checkbox"/> | Sp142 | Atezolilumab (Tecentriq) |
| <input type="checkbox"/> | Sp142 | Atezolilumab (Tecentriq) Plus nab- paclitaxel (Abaxane) |
| <input type="checkbox"/> | 22C3 | Pembrolizumab |

Signature and Contact Number of (Requester):